Want to see HK:1355 full AI Analyst Report?
Top Page
Legend Strategy International Holdings Group Co., Ltd.
(1355)
Select Model
Select Model
Rating:47Neutral
Price Target:
HK$0.17
â–²(18.57% Upside)
Action:Reiterated
Date:07/31/26
Overall score is held down primarily by very weak financial performance (deep multi-year losses, negative equity, and 2025 cash burn). Technicals provide a partial offset with the stock trading above major moving averages, but valuation remains challenged due to negative earnings and no provided dividend yield.
Positive Factors
Revenue Rebound
The 2025 top-line recovery indicates renewed business activity after the prior-year decline. Sustained revenue growth could improve operating scale and help restore profitability, although margin improvement remains necessary.
Negative Factors
Persistent Deep Losses
Multi-year losses point to a structural profitability problem rather than a single weak period. The approximately -85% 2025 net margin shows that revenue recovery has not translated into viable earnings, limiting internal funding capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Rebound
The 2025 top-line recovery indicates renewed business activity after the prior-year decline. Sustained revenue growth could improve operating scale and help restore profitability, although margin improvement remains necessary.
Read all positive factors
Legend Strategy International Holdings Group Co., Ltd. (1355) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$245.17M
Dividend YieldN/A
Average Volume (3M)608.08K
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue Growth8.34%
EPS Growth80.94%
CountryHK
Employees94
SectorConsumer Cyclical
Sector Strength84
IndustryTravel Lodging
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,789,597,800
10 Day Avg. Volume222,000
30 Day Avg. Volume608,083
Financial Highlights & Ratios
PEG Ratio-2.47
Price to Book (P/B)-3.42
Price to Sales (P/S)2.35
P/FCF Ratio-2.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Legend Strategy International Holdings Group Co., Ltd. Business Overview & Revenue Model
Company Description
Legend Strategy International Holdings Group Company Limited, an investment holding company, engages in the accommodation operation and consultancy business in the People’s Republic of China. It also provides property facilities management, franch...
Legend Strategy International Holdings Group Co., Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 50.95M | 51.30M | 40.68M | 67.66M | 63.00M | 70.56M |
| Gross Profit | -1.44M | 1.11M | 21.67M | 45.35M | 6.88M | 15.63M |
| EBITDA | -23.00M | -20.66M | 10.48M | -23.72M | 21.93M | 38.07M |
| Net Income | -8.90M | -43.53M | -21.12M | -38.18M | -7.79M | 4.98M |
Balance Sheet | ||||||
| Total Assets | 71.51M | 80.44M | 75.05M | 127.32M | 196.17M | 240.18M |
| Cash, Cash Equivalents and Short-Term Investments | 1.09M | 2.44M | 13.86M | 4.26M | 6.35M | 17.05M |
| Total Debt | 101.91M | 162.19M | 164.99M | 181.60M | 175.86M | 203.62M |
| Total Liabilities | 124.37M | 183.34M | 180.40M | 210.06M | 217.04M | 242.16M |
| Stockholders Equity | -14.39M | -35.25M | -42.35M | -36.35M | 2.18M | 12.32M |
Cash Flow | ||||||
| Free Cash Flow | -11.50M | -49.60M | 24.01M | 34.51M | 6.41M | 14.06M |
| Operating Cash Flow | -4.72M | -32.69M | 24.27M | 35.16M | 9.35M | 30.40M |
| Investing Cash Flow | -29.05M | -29.64M | -250.00K | -644.00K | -2.93M | -16.31M |
| Financing Cash Flow | 22.89M | 50.81M | -11.98M | -34.94M | -19.01M | -19.81M |
Legend Strategy International Holdings Group Co., Ltd. Technical Analysis
Neutral
0.14
Price Trends
0.15
Negative
0.13
Positive
0.12
Positive
Market Momentum
>-0.01
Positive
41.41
Neutral
27.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1355, the sentiment is Neutral. The current price of 0.14 is below the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.15, and above the 200-day MA of 0.12, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.41 is Neutral, neither overbought nor oversold. The STOCH value of 27.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1355.
Legend Strategy International Holdings Group Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$1.87B | 19.00 | 2.28% | 1.92% | 3.53% | -7.65% | |
68 Neutral | HK$816.48M | 2.70 | 8.45% | 5.00% | 6.80% | 67.22% | |
62 Neutral | HK$545.77M | 14.52 | 0.90% | 0.77% | 6.29% | ― | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
51 Neutral | HK$221.80M | -0.26 | -9.18% | 2.88% | 63.78% | 49.79% | |
47 Neutral | HK$245.17M | -9.86 | 35.86% | ― | 8.34% | 80.94% | |
47 Neutral | HK$399.96M | -0.83 | -7.05% | 3.48% | 49.29% | 79.61% |
* Consumer Cyclical Sector Average
HK:1355
Legend Strategy International Holdings Group Co., Ltd.
0.15
0.04
38.74%
HK:0184
Keck Seng Investments (Hong Kong)
2.38
<0.01
0.21%
HK:0201
Magnificent Hotel Investments Limited
0.06
>-0.01
-12.86%
HK:1221
Sino Hotels (Holdings) Ltd.
1.56
0.21
15.13%
HK:0617
Paliburg Holdings Limited
0.20
-0.12
-38.75%
HK:0078
Regal Hotels International Holdings Limited
0.46
-0.18
-28.13%
Legend Strategy International Holdings Group Co., Ltd. Corporate Events
Biosysen Rights Issue Undersubscribed; Unplaced Shares to Be Marketed via Compensatory Placing
Aug 25, 2026
Biosysen Limited has reported the results of its rights issue, launched on the basis of one rights share for every two existing shares at a subscription price of HK$0.068 per share. The offer comprised 596,532,580 rights shares, all available to q...
Biosysen forecasts swing to profit on lease-termination gain
Aug 24, 2026
Biosysen Limited has issued a positive profit alert indicating that it expects to swing to a net profit of about HK$20 million for the six months ended 30 June 2026, compared with a loss of approximately HK$13.5 million a year earlier. The improve...
Biosysen Sets Board Meeting to Review Interim Results and Potential Dividend
Aug 19, 2026
Biosysen Limited has scheduled a board meeting for 31 August 2026 to review and approve the unaudited interim results of the company and its subsidiaries for the six months ended 30 June 2026. The meeting will also consider a possible recommendati...
Biosysen Completes HK$50 Million Convertible Bond Issue, Paving Way for Ownership Shift
Aug 5, 2026
Biosysen Limited has completed the issuance of HK$50 million in convertible bonds to a major shareholder-linked subscriber, with the subscription price settled through a set-off against an existing loan, fully discharging the company’s repay...
Biosysen Seeks Fivefold Increase in Authorised Share Capital to Support Growth
Aug 5, 2026
Biosysen Limited has proposed increasing its authorised share capital from HK$20 million to HK$100 million, raising the number of authorised shares from 2 billion to 10 billion. The additional 8 billion shares, if issued, will rank pari passu with...
Biosysen Seeks Fivefold Increase in Authorised Share Capital Ahead of August EGM
Aug 4, 2026
Biosysen Limited has called an extraordinary general meeting to seek shareholder approval for a substantial increase in its authorised share capital from HK$20 million to HK$100 million, raising the number of shares from 2 billion to 10 billion. T...
Biosysen Shareholders Back Convertible Bond Financing at EGM
Jul 27, 2026
Independent shareholders of Biosysen Limited have unanimously approved a Subscription and Settlement Agreement and a related financing package at an extraordinary general meeting held on July 27, 2026. The resolution, passed entirely by poll, give...
Biosysen Adjusts Record Date and Book Closure for July 2026 Extraordinary Meeting
Jul 9, 2026
Biosysen Limited has revised the arrangements for shareholder participation in its extraordinary general meeting scheduled for 27 July 2026 in Hong Kong, which will consider the Subscription and Settlement Agreement and a related specific mandate....
Biosysen Plans HK$50 Million Convertible Bond Issue, Calls EGM for Shareholder Approval
Jul 7, 2026
Biosysen Limited, formerly Legend Strategy International Holdings Group Company Limited, is a Cayman Islands-incorporated company listed on the Hong Kong Stock Exchange under stock code 1355. The company is increasingly using equity-linked financi...
Biosysen Limited Delays Circular on Convertible Bond Transaction
Jun 30, 2026
Biosysen Limited has announced a further delay in sending a shareholder circular related to a connected transaction involving the proposed issue of convertible bonds under a specific mandate. The circular, which will include details of the subscri...
BIOSYSEN Announces Non-Underwritten Rights Issue to Raise Up to HK$40 Million
Jun 24, 2026
BIOSYSEN Limited plans a rights issue on the basis of one rights share for every two existing shares held on the record date, at a subscription price of HK$0.068 per share. Based on its current share capital, the company could issue up to 596,532,...
Biosysen says director-linked China Water liquidation has no impact on its operations
Jun 18, 2026
Biosysen Limited has disclosed an update to its director information after independent non-executive director Lam Cheung Shing Richard reported that China Water Industry Group Limited, where he also serves as an INED, has been ordered wound up by ...
Biosysen Delays Circular on Convertible Bond Connected Transaction
Jun 15, 2026
Biosysen Limited has announced a delay in sending a shareholder circular related to a proposed connected transaction involving the issue of convertible bonds under a specific mandate. The circular, which was to detail the subscription and settleme...
Biosysen Names Independent Adviser for Planned Convertible Bond Deal
Jun 1, 2026
Biosysen Limited has appointed Gram Capital Limited as its independent financial adviser to counsel the company’s Independent Board Committee and independent shareholders on a proposed connected transaction involving the issue of convertible...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.